Clinical Trial

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2024-02-23; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2025-01-10
Trial Details
NCT Number NCT06289673
Lead Sponsor St. Jude Children's Research Hospital
Conditions Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Enrollment 850 participants
Start Date 2024-12-26
Primary Completion 2034-05 (estimated)
Study Completion 2039-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-14